Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients

Cancer Treatment and Research

Volumn 157, Issue , 2011, Pages 217-238

  Tonia, Thomy ^a   Bohlius, Julia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL EFFECTIVENESS; DECISION MAKING; ERYTHROCYTE TRANSFUSION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; PATIENT PREFERENCE; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE;

ANEMIA; CLINICAL TRIALS AS TOPIC; HEMATINICS; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 78349250146     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7073-2_13     Document Type: Article

References (40)

1. Marsh WA, Rascati KL. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clin Ther. 1999;21:1443-55.
2. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-14.
3. Jones M, Schenkel B, Just J, Fallowfield L. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. Cancer. 2004;101:1720-32.
4. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005;97:489-98.
5. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epo-etin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-220.
6. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714.
7. Seidenfeld, J, Piper, M, Bohlius, J, Weingart, O, Trelle, S, Engert, A, Skoetz, N, Schwarzer, G, Wilson, J, Brunskill, S, Hyde, C, Bonnell, C, Ziegler, KM, Aronson, N. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. 3. Rockville, MD: Agency for Healthcare Research and Quality; 2006.
8. Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006;28:801-31.
9. Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007;12:1264-73.
10. Bennett C.L., Silver S.M., Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-24.
11. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100:1155-66.
12. Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009;115:706-15.
13. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180(11):E62-71.
14. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15:979-86.
15. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol. 2005;23:6941-8.
16. Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer. 2006;95:1467-73.
17. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008;99:14-22.
18. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27:2838-47.
19. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-42.
20. Lambin P, Ramaekers BL, van Mastrigt GA, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev. 2009;3:CD006158.
21. Quirt I, Micucci S, Moran LA et al. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control. 1997;1:241-8.
22. Couture F, Turner AR, Melosky B et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005;10:63-71.
23. Clark O, Adams JR, Bennett CL et al. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2:23.
24. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407.
25. Henke M, Laszig R, Ruebe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-60.
26. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-60.
27. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5865-8.
28. Aapro M., Spivak J.L. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist. 2009;14(Suppl 1):6-15.
29. Altman D.G., Andersen P.K. Calculating the number needed to treat for trials where the outcome is time to an event. Br Med J. 1999;319:1492-5.
30. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001;18:243-59.
31. Vaupel P, Thews O, Mayer A, Hockel S, Hockel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol. 2002;178:727-31.
32. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hema-tocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90.
33. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
34. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-8.
35. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821-8.
36. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1-14.
37. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-9.
38. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003;98:1514-20.
39. Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res. 2008;14:4685-90.
40. Sinclair AM, Rogers N, Busse L, et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer. 2008;98:1059-67.